Loading
A phase 2/3 trial of iparomlimab and tuvonralimab and anlotinib in lung cancer, run by Sun Yat-sen University, not yet recruiting.
QL1706 Plus Anlotinib as a Later-line Treatment for Patients With Advanced Lung Cancer is a phase 2/3, randomised interventional study registered as NCT07636226 by Sun Yat-sen University, with a registry enrolment figure of 120 participants, started 2026-07-30 and due to reach its primary completion in 2028-12-30. Interventions recorded: QL1706; Anlotinib. Conditions listed: Small Cell Lung Cancer. Primary outcome: OS. Lung eligibility wording from the registry: "Small cell lung cancer or lung squamous cell carcinoma confirmed by tissue or pathological examination". No results are recorded here; the registry entry is the source.
Shares Anlotinib, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Small-cell lung cancer and the tag lung-deep-dive.
Shares Anlotinib, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares Anlotinib, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Small-cell lung cancer and the tag lung-deep-dive.
Shares Anlotinib, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares Anlotinib, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares Anlotinib, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares Anlotinib, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares Anlotinib, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.